AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
Study NCT03375749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing desk intervention
Description: Standing desk converter
Study NCT03375749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Control
Study NCT00000317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone (4mg/day)
Study NCT00000317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00000317 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relapse prevention counseling
Description: Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
Study NCT00000317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention counseling
Description: Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
Study NCT00702793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
Study NCT04033484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
Study NCT04033484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
Study NCT04013750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
Study NCT01899053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules
Study NCT00945555 — intervention group
Intervention type: DRUG
Intervention: Antibacterial agent for the treatment of febrile neutropenia
Description: The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Study NCT02532530 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near-Infrared Spectroscopy (NIRS)
Description: Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
Study NCT01554358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle intervention
Description: The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------
Study NCT02986438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold.
Study NCT02986438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks.
Study NCT02712216 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Determine best port sites to insert bariatric trocars
Study NCT03151603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arctuvan
Description: application of a herbal drug
Study NCT03151603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: application of an antibiotic drug
Study NCT03151603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Arctuvan
Description: application of Placebo to Arctuvan
Study NCT03151603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Fosfomycin
Description: application of Placebo to Fosfomycin
Study NCT04376008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard prostate biopsy
Description: Transperineal TRUS guided standard prostate biopsy (SB).
Study NCT04376008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted and standard prostate biopsy
Description: Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
Study NCT01726608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
Study NCT01726608 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
Study NCT03355781 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance imaging (MRI)
Description: brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
Study NCT03355781 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: 27,5 ml of blood sample : genetic analysis and biobank
Study NCT03355781 — intervention group
Intervention type: OTHER
Intervention: Clinical psychiatric evaluation
Description: Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
Study NCT05222789 — intervention group
Intervention type: PROCEDURE
Intervention: TAP
Description: The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
Study NCT03508440 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intratympanic injection
Description: Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
Study NCT03508440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratympanic injection
Description: Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
Study NCT03508440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Steroid
Study NCT03508440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral Steroid
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.
Study NCT04110587 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: 1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
Study NCT04110587 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Temporomandibular Joint Arthroscopy
Description: Lysis and Lavage
Study NCT04110587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporomandibular Joint Arthroscopy
Description: Lysis and Lavage
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic therapy
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
Study NCT00662909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral
Study NCT00662909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03681639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Metal ion levels determined to monitor changes in chromium and cobalt levels
Description: Analyses was performed pre-operatively, 6 months, 1 year, 2 years and 5 years post-operatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations was analysed by an approved Central Laboratory. The Central Laboratory provided specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory provided the results to the Investigators. The cobalt and chromium was measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
Study NCT01276067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg Tablet
Study NCT03342612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging (MRI)
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroid
Description: Dexamethasone, 4 mg I.V. (Intraoperative)
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid
Description: Dexamethasone, 4 mg I.V. (Intraoperative)
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiinflammatories
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiinflammatories
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesics
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)
Study NCT04110587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)
Study NCT04110587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise program
Description: Home exercise program
Study NCT00931788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents and lipid lowering therapy
Description: The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
Study NCT00931788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
Study NCT03380117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eBridge Online Counseling
Description: In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
Study NCT01899053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Capsules
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Study NCT02177552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Study NCT00748787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Description: 1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
Study NCT00748787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
Study NCT01505049 — intervention group
Intervention type: DRUG
Intervention: quadrivalent HPV vaccine
Description: For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
Study NCT00982228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously once daily. Dose was individually adjusted.
Study NCT00982228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously once daily. Dose individually adjusted.
Study NCT04110587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Home exercise program
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.
Study NCT02112734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU/daily until age 12 months
Study NCT03309150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Mylan
Description: Administration of each formulation will be determined by sequence.
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Accord
Description: Administration of each formulation will be determined by sequence.
Study NCT02014103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Pancea Biotech Limited
Description: Administration of each formulation will be determined by sequence.
Study NCT04401605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Food-supplemented Diet
Description: Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
Study NCT04401605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: No change in diet.
Study NCT04109456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100 mg or 50mg, orally once daily continuously;
Study NCT04109456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg , orally once daily from day 1 to day 21 in a 28-day cycle
Study NCT01793129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
Study NCT01793129 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normothermic Control
Description: Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
Study NCT04109456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: biweekly 840 mg dose will be used in this study starting from Cycle 2.
Study NCT03819101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 100mg
Study NCT03819101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg
Study NCT03882788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
Study NCT03882788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (high dose)
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
Study NCT03882788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (low dose)
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
Study NCT04621565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.